Susquehanna reports 5.2% Purple Biotech (PPBT) ownership stake

Rhea-AI Filing Summary

Susquehanna Securities, LLC filed a Schedule 13G reporting beneficial ownership of 93,953,400 Ordinary Shares of Purple Biotech Ltd., equal to 5.2% of the class. The position is held through 469,767 ADSs, with each ADS representing 200 Ordinary Shares.

Based on the company’s disclosure that 1,806,089,801 Ordinary Shares were outstanding as of October 20, 2025, Susquehanna’s holdings represent a significant but minority passive stake. The filing states the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Purple Biotech.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:18 PM Learn about SEC filing dates

FAQ

What stake in Purple Biotech Ltd. (PPBT) does Susquehanna report?

Susquehanna Securities, LLC reports beneficial ownership of 93,953,400 Ordinary Shares of Purple Biotech Ltd., representing 5.2% of the outstanding class. This makes Susquehanna a significant but minority shareholder based on the company’s disclosed total shares.

How did Susquehanna’s 5.2% ownership in PPBT arise according to the filing?

The filing states Susquehanna’s 5.2% stake consists of 469,767 ADSs, with each ADS representing 200 Ordinary Shares. The position is reported as beneficially owned and held in the ordinary course of business, without an intent to change or influence control.

What is the total share count used to calculate Susquehanna’s 5.2% in PPBT?

Susquehanna cites Purple Biotech’s disclosure that 1,806,089,801 Ordinary Shares were outstanding as of October 20, 2025. Using this figure, its 93,953,400 shares correspond to a 5.2% beneficial ownership of the company’s Ordinary Shares.

Is Susquehanna’s position in Purple Biotech (PPBT) passive or activist?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Purple Biotech. This language characterizes Susquehanna’s disclosed 5.2% stake as a passive investment.

What voting and dispositive power does Susquehanna report over PPBT shares?

Susquehanna reports 93,953,400 shares with sole voting power and sole dispositive power, and the same amount under shared power fields on the cover page. These figures indicate the extent of control it can exercise over its reported holdings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Purple Biotech Ltd.

(Name of Issuer)

Ordinary Shares, no par value per share

(Title of Class of Securities)

74638P208

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74638P208

1

Names of Reporting Persons

Susquehanna Securities, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 93,953,400.00
6	Shared Voting Power 93,953,400.00
7	Sole Dispositive Power 93,953,400.00
8	Shared Dispositive Power 93,953,400.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

93,953,400.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

BD, OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Purple Biotech Ltd.
(b)	Address of issuer's principal executive offices: 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel
Item 2.
(a)	Name of person filing: This statement is filed by Susquehanna Securities, LLC, who is referred to herein as the "Reporting Person" with respect to the shares of Ordinary Shares, no par value per share (the "Shares"), of Purple Biotech Ltd. (the "Company").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of the Reporting Person is: 401 E. City Avenue Suite 220 Bala Cynwyd, PA 19004
(c)	Citizenship: Citizenship is set forth in Row 4 of the cover page for the Reporting Person and is incorporated herein by reference.
(d)	Title of class of securities: Ordinary Shares, no par value per share
(e)	CUSIP No.: 74638P208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The number of Shares reported as beneficially owned by Susquehanna Securities, LLC consists of 469,767 ADSs. Each ADS represents two hundred (200) Shares. The Company's Notice of Extraordinary General Meeting of Shareholders attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 on Form 6-K, filed October 28, 2025 indicates that there were 1,806,089,801 Shares outstanding as of October 20, 2025.
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by this Item 4(c)(ii) is set forth in Row 6 of the ccover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Susquehanna Securities, LLC

Signature:	/s/ Brian Sopinsky
Name/Title:	Brian Sopinsky, Secretary
Date:	02/12/2026